These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22995323)

  • 1. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.
    Moss RB; Mistry SJ; Konstan MW; Pilewski JM; Kerem E; Tal-Singer R; Lazaar AL;
    J Cyst Fibros; 2013 May; 12(3):241-8. PubMed ID: 22995323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
    Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
    Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
    Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
    Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
    Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
    Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
    Miller BE; Mistry S; Smart K; Connolly P; Carpenter DC; Cooray H; Bloomer JC; Tal-Singer R; Lazaar AL
    BMC Pharmacol Toxicol; 2015 Jun; 16():18. PubMed ID: 26092545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
    De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
    Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
    Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
    J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
    Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
    Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
    Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
    Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
    Vargas MH; Del-Razo-Rodríguez R; López-García A; Lezana-Fernández JL; Chávez J; Furuya MEY; Marín-Santana JC
    BMC Pulm Med; 2017 Dec; 17(1):206. PubMed ID: 29246256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
    Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B;
    Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
    Leaker BR; Barnes PJ; O'Connor B
    Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
    Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
    Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial.
    Griese M; Kappler M; Eismann C; Ballmann M; Junge S; Rietschel E; van Koningsbruggen-Rietschel S; Staab D; Rolinck-Werninghaus C; Mellies U; Köhnlein T; Wagner T; König S; Teschler H; Heuer HE; Kopp M; Heyder S; Hammermann J; Küster P; Honer M; Mansmann U; Beck-Speier I; Hartl D; Fuchs C; ; Hector A
    Am J Respir Crit Care Med; 2013 Jul; 188(1):83-9. PubMed ID: 23631796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
    Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
    Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.